GH Research (GHRS) Income from Continuing Operations (2020 - 2026)
GH Research (GHRS) posted quarterly Income from Continuing Operations of 14137000.0 for Q4 2025, down 60.61% year-over-year from 35890935.68 in Q4 2024, and down 0.83% quarter-over-quarter from 14020000.0 in Q3 2025.
GH Research (GHRS) Income from Continuing Operations (2020 - 2026) Analysis & Trends
GH Research's Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 14137000.0 for Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 60.61% year-over-year to 14137000.0; the TTM figure through Dec 2025 stood at 48258000.0 (down 23.86% YoY), while the FY2025 annual figure was 48258000.0, down 23.86% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 14137000.0, down from 14020000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 334000.0 in Q2 2022, with the low at 23160000.0 in Q4 2022.
- The 5-year median for Income from Continuing Operations is 9045500.0 (2024), against an average of 8357050.0.
- The sharpest annual moves came in 2021 and 2022: Income from Continuing Operations slumped 3036.62% in 2021, then surged 115.72% in 2022.
- GH Research's Income from Continuing Operations stood at 10194000.0 in 2021, then plunged by 127.19% to 23160000.0 in 2022, then soared by 51.33% to 11272000.0 in 2023, then advanced by 21.91% to 8802000.0 in 2024, then plunged by 60.61% to 14137000.0 in 2025.
- Business Quant data shows GHRS's Income from Continuing Operations at 14137000.0 in Q4 2025, 14020000.0 in Q3 2025, and 9289000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | -17.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.75 Mn |
| Dec 31, 2025 | -14.14 Mn |
| Sep 30, 2025 | -14.02 Mn |
| Jun 30, 2025 | -9.29 Mn |
| Mar 31, 2025 | -10.81 Mn |
| Dec 31, 2024 | -8.80 Mn |
| Sep 30, 2024 | -12.11 Mn |
| Jun 30, 2024 | -10.38 Mn |
| Mar 31, 2024 | -7.67 Mn |
| Dec 31, 2023 | -11.27 Mn |
| Sep 30, 2023 | -5.65 Mn |
| Jun 30, 2023 | -7.73 Mn |
| Mar 31, 2023 | -10.94 Mn |
| Dec 31, 2022 | -23.16 Mn |
| Sep 30, 2022 | -441,000.00 |
| Jun 30, 2022 | 334,000.00 |
| Mar 31, 2022 | -5.76 Mn |
| Dec 31, 2021 | -10.19 Mn |
| Sep 30, 2021 | -1.84 Mn |
| Jun 30, 2021 | -2.13 Mn |